LTX-315, an oncolytic peptide, to convert immunogenically 'cold' tumors to 'hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

被引：5
|
作者：
Spicer, James F.
Baurain, Jean -Francois
Awada, Ahmad
Kristeleit, Rebecca Sophie
Jossang, Dag Erik
Marabelle, Aurelien
Loirat, Delphine
Wold, Hedda
Nicolaisen, Berit
Rekdal, Oystein
Olsen, Wenche Marie
Saunders, Andrew
Brunsvig, Paal
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3085
引用
收藏
页数：6
相关论文
共 50 条
  • [1] LTX-315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebecca
    Jossang, Dag-Erik
    Jebsen, Nina-Louise
    Loirat, Delphine
    Saunders, Andrew
    Olsen, Wenche
    Nicolaisen, Berit
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke Sundvold
    Rekdal, Oystein
    Brunsvig, Pal
    Galon, Jerome
    Hermitte, Fabienne
    Gjertsen, Bjorn-Tore
    Armstrong, Anna
    Spicer, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] A phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced sarcoma
    Baaurain, Jean-Francois
    Jungels, Christiane
    Kristeleit, Rebecca S.
    Jossang, Dag E.
    Jebsen, Nina L.
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke S.
    Brunsvig, Paal
    Galon, Jerome
    Hermitte, Fabienne
    Patel, Hamina
    CANCER RESEARCH, 2019, 79 (13)
  • [3] A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebbecca S.
    Loirat, Delphine
    Jossang, Dag E.
    Jebsen, Nina L.
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    Gjerstad, Vibeke S.
    Brunsvig, Paal
    Galon, Jerome
    Hermitte, Fabienne
    Patel, Hamina
    Spicer, James
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Intratumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours
    Spicer, J.
    Awada, A.
    Brunsvig, P.
    Saunders, A.
    Olsen, W. M.
    Nicolaisen, B.
    Rekdal, O.
    Laruelle, M.
    Marjuadi, F.
    Vakili, J.
    Aftimos, P.
    Barthelemy, P.
    Deva, S.
    Baurain, J. F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S113 - S113
  • [5] A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.
    Spicer, James F.
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Awada, Ahmad
    Kristeleit, Rebecca Sophie
    Jossang, Dag Erik
    Jebsen, Nina
    Loirat, Delphine
    Armstrong, Anne Caroline
    Curigliano, Giuseppe
    Nicolaisen, Berit
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    Gjerstad, Vibeke Sundvold
    Brunsvig, Paal
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
    Spicer, James
    Marabelle, Aurelien
    Baurain, Jean-Francois
    Jebsen, Nina Louise
    Jossang, Dag Erik
    Awada, Ahmad
    Kristeleit, Rebecca
    Loirat, Delphine
    Lazaridis, George
    Jungels, Christiane
    Brunsvig, Paal
    Nicolaisen, Berit
    Saunders, Andrew
    Patel, Hamina
    Galon, Jerome
    Hermitte, Fabienne
    Camilio, Ketil Andre
    Mauseth, Brynjar
    Sundvold, Vibeke
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2755 - 2763
  • [7] A phase I study with LTX-315, an immunogenic cell death inducer, in patients with transdermally accessible tumors.
    Brunsvig, Peal
    Aamdal, Steiner
    Kolstad, Arne
    Haaskjold, Olav Inge
    Miller, Robert M.
    Rekdal, Oystein
    Nicolaisen, Berit
    Olsen, Wenche Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxoliplatin in patients with advanced or metastatic solid tumours:: Results from a phase I study.
    Evans, J
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Baselga, J
    Bissett, D
    Regueiro, P
    Rubio, ED
    ANNALS OF ONCOLOGY, 2000, 11 : 51 - 51
  • [9] A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)
    Baurain, Jean-Francois
    Awada, Ahmad
    Brunsvig, Paal F.
    Kristeleit, Rebecca
    Loirat, Delphine
    Jossang, Dag Eirik
    Zitvogel, Laurence
    Kroemer, Guido
    Marabelle, Aurilien
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    Wold, Hedda
    Nicolaisen, Berit
    Saunders, Andrew
    Spicer, James
    CANCER RESEARCH, 2017, 77
  • [10] Ongoing phase I study of pemetrexed combined with gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumors
    Boiling, Claus
    Luebbing, Corinna
    Graefe, Tobias
    Fleeth, Jochen
    von Scheel, Jobst
    Luedtke, Frank E.
    Mueller-Hagen, Sigrun
    Depenbrock, Henrik
    Ohnmacht, Ute
    Hanauske, Axel-R
    ANNALS OF ONCOLOGY, 2004, 15 : 104 - 104
12345